Latest Conference Articles

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Robert Ang, MD, discusses highlights of his AAO 2020 presentation on a study analyzing the vIsual outcomes of a small-aperture IOL implantation in patients with a history of post-laser refractive surgery.

Richard Lehrer, MD, speaks on the highlights of a study analyzing the success of SLT after trabecular bypass stenting / phacoemulsification, presented during AAO 2020.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.

During AAO 2020, Cathy G. Cohen, MHSA, CAE, AAO vice president for governmental affairs, offered some optimism for the future of health care under the Biden administration.

A unique Behind-the-Scenes series from the American Academy of Ophthalmology Truhlsen-Marmor Museum of the Eye kicks off November 18, from noon to 1 pm Pacific, with “The National Trachoma Service.” Register now for this event.

Robert Weinstock, MD, presents data from a retrospective multicenter study focusing on the efficacy of dexamethasone intraocular suspension 9% delivered at the time of cataract surgery.

Robert Weinstock, MD, presents data from a retrospective multicenter study focusing on the efficacy of dexamethasone intraocular suspension 9% delivered at the time of cataract surgery.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

Speaking during the American Academy of Ophthalmology’s virtual 2020 annual meeting, Neal H. Shorstein, MD, explained how physicians at Kaiser Permanente have been using a prophylactic drop-free drug regimen before cataract surgery for more than a decade. Their regimen is so streamlined that the only drop that patients receive in anticipation of cataract surgery is a supplemental dilation drop instilled preoperatively while they are still in the holding area.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.